ArticleThe Journal of investigative dermatology2021
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Open access · greenAbstract read
In one paragraph
Article in The Journal of investigative dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Molecular biomedicine · 2026Review
- Mechanistic and preclinical evaluation of SIRT3 as a therapeutic target in melanoma.Journal of dermato-oncology · 2026Article
- VCAN Is Essential for ERK5-Driven Tumorigenesis in Soft Tissue Sarcoma.International journal of biological sciences · 2026Article
- Dual-Specificity Protein Phosphatases Targeting Extracellular Signal-Regulated Kinases: Friends or Foes in the Biology of Cancer?International journal of molecular sciences · 2025Review
- Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- circRNA18_46222157_46248185 inhibits melanogenesis by targeting miR-211/EP300 pathway in goat melanocytes.Animal bioscience · 2025Article
- Non-coding RNAs in BRAF-mutant melanoma: targets, indicators, and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma.Current treatment options in oncology · 2024Review
- The Expression of miR-211-5p in Sentinel Lymph Node Metastases of Malignant Melanoma Is a Potential Marker for Poor Prognosis.International journal of molecular sciences · 2024Article
- miRNA-211 maintains metabolic homeostasis in medulloblastoma through its target gene long-chain acyl-CoA synthetase 4.Acta neuropathologica communications · 2023Article
- A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma.Cancer gene therapy · 2023Article
- BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge.Cancers · 2023Review
- Critical Considerations for Investigating MicroRNAs during Tumorigenesis: A Case Study in Conceptual and Contextual Nuances of miR-211-5p in Melanoma.Epigenomes · 2023Review
- Article
- Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib.Cell death & disease · 2022Article
- The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.Molecular oncology · 2022Review
- Review
- The MEK5/ERK5 Pathway in Health and Disease.International journal of molecular sciences · 2021Review
- BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.Cancers · 2021Article
- The Melanocyte Lineage Factor miR-211 Promotes BRAFThe Journal of investigative dermatology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 1 country.
Bongyong LeeDepartment of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Anupama SahooSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Junko SawadaSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA; Department of Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
John MarchicaSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Sanjay SahooSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Fabiana I A L LayngSanford Burnham Prebys Medical Discovery Institute, NCI-Designated Cancer Center, La Jolla, California, USA.
Darren FinlaySanford Burnham Prebys Medical Discovery Institute, NCI-Designated Cancer Center, La Jolla, California, USA.
Joseph MazarSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA.
Piyush JoshiDepartment of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Masanobu KomatsuSanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA; Department of Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA.
Kristiina VuoriSanford Burnham Prebys Medical Discovery Institute, NCI-Designated Cancer Center, La Jolla, California, USA.
Petrus R de JongSanford Burnham Prebys Medical Discovery Institute, NCI-Designated Cancer Center, La Jolla, California, USA.
Animesh RayKeck Graduate Institute, Claremont, California, USA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, USA.
Ranjan J PereraDepartment of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Sanford Burnham Prebys Medical Discovery Institute, Orlando, Florida, USA; Department of Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA; Sanford Burnham Prebys Medical Discovery Institute, NCI-Designated Cancer Center, La Jolla, California, USA. Electronic address: jperera2@jhmi.edu.7.
Sanford Burnham Prebys Medical Discovery Institute · USJohns Hopkins University · USCalifornia Institute of Technology · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MIdentification of the molecular mechanism of miR-211 and its target genes in melanocytes and pigmented melanoma senescence and apoptosisR21CA202197 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PERERA, RANJAN JOSEPH · 2016 to 2017
$467kThe role of miR-211 and its target genes in melanoma development in humans.R03CA172847 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PERERA, RANJAN JOSEPH · 2013 to 2014
$195kIdentification and characterization of long noncoding RNAs in human melanomasR03CA165184 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PERERA, RANJAN JOSEPH · 2012 to 2013
$189kNCI NIH HHS P30 CA006973NCI NIH HHS P30 CA030199NCI NIH HHS R03 CA165184NCI NIH HHS R03 CA172847NCI NIH HHS R21 CA202197
Abstract
MicroRNAs (miRs) are important posttranscriptional regulators of cell fate in both normal and disease states. miR-211 has previously been shown to be a direct regulator of metabolism in BRAF
Indexed as
AnimalsAzetidinesCell Line, TumorCell ProliferationDrug Resistance, NeoplasmDual Specificity Phosphatase 6Gene Knockdown TechniquesHumansMAP Kinase Signaling SystemMelanomaMiceMicroRNAsMitogen-Activated Protein Kinase 7MutationPhosphorylationPiperidinesAzetidinesBRAF protein, humancobimetinibDual Specificity Phosphatase 6DUSP6 protein, humanMAPK7 protein, humanMicroRNAsMIRN211 microRNA, humanMitogen-Activated Protein Kinase 7PiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.